Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6

Machado et al. 2008. J. Exp. Med. doi:10.1084/jem.20072416 [OpenUrl][1][Abstract/FREE Full Text][2] [1]: {openurl}?query=rft_id%253Dinfo%253Adoi%252F10.1084%252Fjem.20072416%26rft_id%253Dinfo%253Apmid%252F18411340%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%

[1]  C. Serhan.  Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[2]  R. Floto.  Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5 , 2008, European Respiratory Review.

[3]  F. Erkekol,et al.  Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[5]  Z. Cao,et al.  IRAK: A Kinase Associated with the Interleukin-1 Receptor , 1996, Science.

[6]  W. Aird,et al.  PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. , 2001, American journal of physiology. Heart and circulatory physiology.

[7]  J. Andersen,et al.  Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells , 2003, Nature Immunology.

[8]  C. Serhan,et al.  Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases , 2003, Journal of dental research.

[9]  D. Gilroy,et al.  15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation , 2004, The Journal of experimental medicine.

[10]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[11]  C. Ware,et al.  TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. , 1996, The Journal of biological chemistry.

[12]  A. Flores-Morales,et al.  Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. , 2006, Cytokine & growth factor reviews.

[13]  A. Sher,et al.  Parasite-induced Lipoxin A4 Is an Endogenous Regulator of IL-12 Production and Immunopathology in Toxoplasma gondii Infection , 2002, The Journal of experimental medicine.

[14]  A. Sher,et al.  CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. , 2000, Nature immunology.

[15]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[16]  J. Pober,et al.  Tumor necrosis factor receptor-associated factors (TRAFs) , 2001, Oncogene.

[17]  J. F. Burrows,et al.  SOCS3 Targets Siglec 7 for Proteasomal Degradation and Blocks Siglec 7-mediated Responses* , 2006, Journal of Biological Chemistry.

[18]  H. Shu,et al.  TRAF7 Potentiates MEKK3-induced AP1 and CHOP Activation and Induces Apoptosis* , 2004, Journal of Biological Chemistry.

[19]  Young Chul Park,et al.  All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. , 2002, Journal of cell science.

[20]  A. Sher,et al.  Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasma gondii , 1996, Infection and immunity.

[21]  A. Sher,et al.  Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. , 2005, The Journal of clinical investigation.

[22]  G. Trinchieri,et al.  The Interleukin 12 P40 Gene Promoter Is Primed by Interferon ~/in Monocytic Cells , 1996 .

[23]  J. Aliberti.  Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma GONDII , 2005, Nature Reviews Immunology.

[24]  C. Serhan,et al.  Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Sher,et al.  Mice Deficient in LRG-47 Display Enhanced Susceptibility to Trypanosoma cruzi Infection Associated with Defective Hemopoiesis and Intracellular Control of Parasite Growth , 2005, The Journal of Immunology.

[26]  J. Aliberti,et al.  Impact of lipoxin-mediated regulation on immune response to infectious disease , 2006, Immunologic research.

[27]  Masato Kubo,et al.  SOCS proteins, cytokine signalling and immune regulation , 2007, Nature Reviews Immunology.

[28]  J. Uddin,et al.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.

[29]  W. Alexander,et al.  The SOCS box: a tale of destruction and degradation. , 2002, Trends in biochemical sciences.

[30]  S. Abramson,et al.  Modes of action of aspirin-like drugs. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Johndrow,et al.  Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent , 2006, Nature Medicine.

[32]  A. Sher,et al.  Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. , 1999, Immunity.

[33]  A. Sher,et al.  In Vivo Microbial Stimulation Induces Rapid CD40 Ligand–independent Production of Interleukin 12 by Dendritic Cells and their Redistribution to T Cell Areas , 1997, The Journal of experimental medicine.

[34]  C. Hunter,et al.  TRAF6-Dependent Mitogen-Activated Protein Kinase Activation Differentially Regulates the Production of Interleukin-12 by Macrophages in Response to Toxoplasma gondii , 2004, Infection and Immunity.

[35]  K. R. Ely,et al.  Differential Requirements for Tumor Necrosis Factor Receptor-associated Factor Family Proteins in CD40-mediated Induction of NF-κB and Jun N-terminal Kinase Activation* , 1999, The Journal of Biological Chemistry.

[36]  P. Mackowiak.  Brief history of antipyretic therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  C. Godson,et al.  Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. , 2004, Kidney international.

[38]  A. Sher,et al.  Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity , 2002, Nature Immunology.